Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany

Doubts About Blockbuster Prospects Linger

Executive Summary

BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.

You may also be interested in...

New Gene Therapies Have Hit The Market; Drug Makers Discuss Initial Launch Trends

BioMarin, Sarepta and bluebird bio are all launching new gene therapies in the US. The drug makers updated investors on the commercial execution during second quarter financial earnings calls.

Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong

BioMarin has finally brought its hemophilia A gene therapy Roctavian market and is determined prove naysayers wrong, but must work with its limitations and a confusing US label.

Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain

The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts